Matthew Breton

Process Development Associate at Sangamo Therapeutics Inc

Matthew Breton's Professional Contact Details

Email (Verified)

****@sangamo.com

Get Email Address

(510) 970-6000

Location

San Francisco, California, US

Company

Sangamo Therapeutics Inc

Person Seniority

entry

Matthew Breton's Current Company Details

Sangamo Therapeutics Inc

California, US • 118 Employees

biotechnology

Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company is conducting Phase 1/2 clinical trials in Hemophilia A and Hemophilia B, and lysosomal storage disorders MPS I and MPS II. Sangamo has an exclusive, global collaboration and license agreement with Pfizer Inc. for gene therapy programs for Hemophilia A, with Bioverativ Inc. for hemoglobinopathies, including beta thalassemia and sickle cell disease, and with Shire International GmbH to develop therapeutics for Huntington's disease. In addition, it has established strategic partnerships with companies in non-therapeutic applications of its technology, including Sigma-Aldrich Corporation and Dow AgroSciences. For more information about Sangamo, visit the Company's website at www.sangamo.com.

Public Symbol

SGMO

Founded Year

1995

Organization Website

sangamo.com

Organization Languages

English

Organization Revenue

39500

Alexa Ranking

655908